Recipharm publishes Annual report 2014
Recipharm publishes today its Annual report for 2014 on www.recipharm.com. The Annual report is available in Swedish and English. The English version is also integrated with a review of the Company’s business.
The complete Annual report in English is also attached to this announcement.
Recipharm’s Annual General Meeting is held on 7 May 2015.
For more information please contact:
Björn Westberg, CFO, firstname.lastname@example.org, telephone: +46 8 602 46 20
This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm. This information was submitted for publication on 16 April 2015, at 09:00 am CET.
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com